|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01099 SINOPHARM
Nominal 
25.050 -0.600 (-2.339%) | 2022/12 - Final RMB(K¥) | %Chg (Final to Final) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | 2018/12 RMB(K¥) | ||
| Turnover | 552,147,550 | 5.968% | 521,051,235 | 456,414,611 | 425,272,726 | 344,525,821 | |
| Cost of Sales | (504,713,490) | 5.810% | (477,000,627) | (416,091,300) | (387,741,423) | (313,297,729) | |
| Gross Profit | 47,434,060 | 7.681% | 44,050,608 | 40,323,311 | 37,531,303 | 31,228,092 | |
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (666,467) | 11.360% | (598,478) | (750,224) | (416,391) | (357,336) | |
| Profit / (Loss) on Disposal | (1,936,170) | 71.218% | (1,130,821) | (1,273,561) | (1,950,177) | (1,328,832) | |
| Other Non-operating Items | 82,278 | -- | (375,813) | (202,327) | (120,544) | 81,828 | |
| Share of Results of Asso. & JCEs | 1,067,067 | -0.262% | 1,069,868 | 987,463 | 887,074 | 843,169 | |
| Profit / (Loss) before Taxation | 18,563,819 | 9.179% | 17,003,162 | 15,598,096 | 13,759,810 | 12,207,940 | |
| Taxation | (4,218,377) | 7.109% | (3,938,389) | (3,500,805) | (3,139,738) | (2,803,456) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (5,819,787) | 9.681% | (5,306,127) | (4,910,013) | (4,367,535) | (3,568,642) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 8,525,655 | 9.886% | 7,758,646 | 7,187,278 | 6,252,537 | 5,835,842 | |
| Net Finance Costs / (Income) | 3,189,992 | -6.256% | 3,402,869 | 2,944,189 | 3,137,424 | 2,766,396 | |
| Depreciation & Amortisation | 4,165,019 | 6.195% | 3,922,058 | 3,597,114 | 3,114,076 | 1,394,679 | |
| Directors' Emoluments | -- | -- | 15,277 | 21,942 | 25,462 | 20,543 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified | |
Market Valuation Indicators
| EPS (cts) | 273.000 | -- | 249.000 | 231.000 | 211.000 | 197.000 |
| DPS (cts) | 82.000 | -- | 75.000 | 69.000 | 60.000 | 59.000 |
| Dividend Payout Ratio (%) | 30.037% | -- | 30.120% | 29.870% | 28.436% | 29.949% |
| Cash flow per share ($) | -- | -- | 2.983 | 3.585 | 6.323 | 1.231 |
| NBV per share ($) | 21.812 | -- | 19.831 | 18.060 | 15.958 | 14.410 |
| Remarks: | Real time quote last updated: 31/05/2023 11:34 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 8,525,655 |
| %Change | 9.886% |
| EPS / (LPS) | RMB 2.730 |
| NBV Per Share (¥) | RMB 21.812 |